Skip to main content
Equibles

NATCOPHARM · Natco Pharma Limited · Financials

Use NATCOPHARM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NATCOPHARM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
810.45 INR +1.65 (+0.20%) At close · Nov 13 Earnings today
Rebalance outlook locked
Market Cap
158.98B INR
Shares
196.17M
Volume · Nov 13 3.1M Avg daily vol (3M) 520.56K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
40.78B -7.9%
FY2026 Revenue FY2018–FY2026
Net Income
14.19B -24.8%
FY2026 Net Income FY2018–FY2026
Operating Cash Flow
17.68B +4.2%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
INR 30.89B 40.78B 44.3B 39.99B 27.07B 19.45B 20.52B 19.15B 20.95B 22.02B
INR 1.93B 2.07B 2.35B 1.87B 1.64B 1.43B 1.17B 998M 810M 662M
INR 510M 367M 239M 192M 145M 177M 133M 215M 193M 154M
INR — — 22.91B 16.74B 8.62B 2.02B 5.8B 5.69B 8.25B 8.87B
INR 647M 1.19B 4.08B 2.85B 1.47B 322M 1.37B 1.11B 1.82B 1.92B
INR 8.29B 14.19B 18.85B 13.88B 7.15B 1.7B 4.41B 4.61B 6.44B 6.96B
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 5.51B in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.